DeepTech Investor Summit

ALP Bio AG

ETH spin-off

alpbio.ai/Zurich, Switzerland
13 profile visits

About

ALP AI is a biotech startup building an AI-driven platform to de-risk and improve antibody drug candidates by predicting and reducing immunogenicity / Anti-Drug Antibody (ADA) responses.

The core idea is a closed-loop system:

  • Generative AI / protein language models propose sequence improvements (reduce ADA risk without hurting efficacy)

  • A human immune validation layer using tonsil-derived immune organoids tests real immune reactivity

  • Results feed back into the models to continuously improve prediction and design quality

ALP AI aims to become a key “immunogenicity infrastructure” partner for biologics R&D, supporting biotech and pharma teams in early-stage selection + antibody re-engineering to avoid failures later in clinical development.

Target Markets of your organization / Expansion or target markets of your spin-off

SwitzerlandUSEMEA

Covered funding stages of your organization / Spin-off Funding Stage

Pre-Seed

Industry Sector your organization invests in / Industry Sector of your Spin-off

Bio Tech

Representatives

ALP Bio AG

Co-Founder, CEO

ALP Bio AG

Marketplace (1)